NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW.
Go here to read the rest:
Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025
TORONTO and HAIFA, Israel, April 19, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce that Dr. Lior Shaltiel, CEO and Director at NurExone, was invited to present on "Revolutionizing Spinal Cord Injury Treatment: Harnessing the Potential of Exosomes for Advanced Therapy in Comprehensive Approach" at the Exosomes of Europe conference in London in June, 2024.
Read the rest here:
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine
Correction to Company announcement – No. 23 / 2024
Go here to see the original:
Correction to Company announcement – No. 23 / 2024
CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced its intention to voluntarily delist from the Nasdaq Global Market (“Nasdaq”) and to deregister its Class A common stock under Section 12(b) and Section 12(g) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and suspend its reporting obligations under Section 15(d) of the Exchange Act.
Read more here:
Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock
EDISON, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, today announced that it has begun wind-down activities in its ASCEND-NASH Trial, while continuing to explore strategic alternatives, as previously announced in December 2023.
Original post:
Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial
SAN MATEO, Calif. and SINGAPORE, April 19, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it received a letter (the “Letter”) on April 18, 2024 from The Nasdaq Stock Market (“Nasdaq”) informing the Company that it failed to maintain the continued listing requirement under Nasdaq Listing Rule 5550(b)(1) for the Nasdaq Capital Market, which requires that a listed company’s stockholders’ equity be at least $2.5 million (the “Stockholders’ Equity Requirement”).
Go here to read the rest:
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice
FLORHAM PARK, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (the “Company”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that on April 17, 2024, the Company received notification from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Annual Report on Form 10-K for the year ended December 31, 2023, it is no longer in compliance with Nasdaq’s continued listing requirements which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission. Nasdaq’s notice has no immediate effect on the listing of Celularity’s common stock and warrants, which continue to trade on the Nasdaq Capital Market under the symbols “CELU” and “CELUW,” respectively.
Go here to read the rest:
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced issued a letter to shareholders from its Co-founder and Executive Chairman, Lou Reese and Chief Executive Officer, Mei Mei Hu.
Original post:
Vaxxinity Issues Shareholder Letter
This is Uncomfortable April 18, 2024 Transcript
Note: Marketplace podcasts are meant to be heard, with emphasis, tone and audio elements a transcript cant capture. Transcripts are generated using a combination of automated software and human transcribers, and may contain errors. Please check the corresponding audio before quoting it.
Reema Khrais: Its a beautiful home.
Doris Tyler: Oh, thank you, we love it.
Reema: Im entering a cozy townhouse in Banner Elk, North Carolina. Its tucked away among beautiful mountains with snow on their peaks. Im here to meet Doris Tyler.
Doris: Would you like some water or coffee or anything?
Reema: Im good, thank you so much
Reema: Her home is cozy. Its December. Theres a Christmas tree, wood burning in the fireplace, and family photos everywhere you look
Doris: Im glad you got to come and see the beautiful mountain country we live in up here.
Reema: I know! Its so beautiful
Reema: Right away I feel the type of person Doris is. Full of energy despite her 80 some years. Incredibly warm. We sit down to talk. Her feet dangle from the couch.
Reema: So how would friends and family describe you?
Doris: One of my granddaughters called me Crazy Granny.
Reema: *laugh* Why is that?
Doris: Uh, Im very lively. I love people, I love to meet new people, um, I love hugs.
Reema: How, how would you describe her?
Don: That she loves life.
Reema: Thats Doriss husband, Don. Hes sitting on a recliner across from her. I notice when Doris talks, she becomes his only focus.
Doris: We met singing in the choir and actually started dating on, um, choir tour to California. And, um, I dont know if I should say this but my, he first kissed me in Bernardino, California.
Reema: Aw! Was there, I dont know, like a song early on that you all really connected over?
Doris: Uh, it was When I Fall in Love by Nat King Cole.
MUSIC: When I fall in love it will be forever
Reema: The song says, when I fall in love, it will be forever
Doris: Don said that to me when he kissed me that day in Bernardino, and so thats why.
Reema: Don was enamored with Doriss energetic personality and how unafraid she was to be herself. Like when shed go to baseball games, shed yell so loud her family would joke they could hear her from home. Their romance moved fast.
Doris: We got back from choir tour on April 1st and April 18th we were engaged.
Reema: Wow!
Doris: And we were married August 11th.
Reema: Yall wasted no time!
Doris: And everyone said it wouldnt last! And here it is 61 years.
Reema: Don and Doris lived a happy life together. Both would go on to teach music: Doris taught elementary school and Don taught college. They didnt make a lot of money, but it was enough. Doris was very active, even after retirement. She loved doing things for herself and for her church. And then one day, everything changed.
Doris was driving to a womens meeting at her church. It was starting to get dark. And then it started to rain.
Doris: And cars started coming towards me, and I couldnt, I couldnt see to judge exactly where I was on the road. And, um, so, uh, the further I got, the slower I was driving, trying to, uh, you know, be careful and not run off the road or not hit somebody.
Reema: Her vision was so blurry she could barely see. The road from her home was a little curvy, but Doris had driven this way so many times, it should have been automatic.
Doris: And the more, the more I went, the more, um, upset I got. And I finally just pulled into a parking lot. And I turned around and crept back home.
Reema: When she came inside, Don was surprised to see the state she was in.
Doris: And I was boohooing, boohooing, and Don thought Id had a wreck, because of the way I was. And I told him, when I got in there, I said, I am never, ever driving again! I just was so afraid that I would hurt or kill someone if I, you know, if I caused a wreck, and I just, I couldnt do that. I just couldnt do that. Id rather give up driving than do that.
Reema: Doris went to her eye doctor and learned that she had macular degeneration, which is a common eye disease among older people. It causes the center of your vision to be blurry.
There was good news and bad news: The good news was that she could treat the condition with injections, and that should stop her vision from getting too much worse. With her social security benefits, those injections would cost 200 dollars a month, which seemed more than worth it. The bad news was that her vision would probably never be the same again.
So Doris started getting those injections each month. The idea of a needle in her eye sounded terrifying at first, but she quickly got used to it.
Life went on like that for a while. Don helped Doris as much as he could. Doris could no longer read the small print in her music or her recipes, so Don would type them up for her in bigger fonts.
Don: I mean, I was always on the computer doing something, you know, so I just typed the words for her or whatever that she needed as far as the recipes, didnt seem like that big a deal.
Reema: And then, suddenly, in 2016, the injections stopped working. The doctor told her, theres this other type of injection you can try. But instead of $200 a month, it would cost $2000 a month. Ten times as much. There was just no way they could afford it.
Don and Doris had just about lost hope, when a friend handed them a booklet. The print was small, and Doris couldnt read it, so Don read it aloud to her. It basically described a new technology: stem cells, that could cure all kinds of ailments. The idea was that you could take cells from a healthy part of the body and inject them into a damaged part of the body, and the healthy cells would help the damaged cells heal and regenerate.
Doris learned she could get stem cell injections in her eyes to restore her vision. The procedure would cost $8000 for both eyes.
Reema: At the time, what was $8000 like for you all?
Doris: Well, I, I just said to Don, We cant do it.
Reema: They were retired school teachers who didnt have even 8000 dollars in their savings account. But then, Doriss children had an idea: they insisted on setting up a GoFundMe for her.
Doris: My boys, my sons, they said, Mom, you need to get this, uh, done. You know, this would help you so much.
Reema: Doris had never heard of GoFundMe. She had never heard of stem cells, either. But she did want her vision back.
Im Reema Khrais and youre listening to This is Uncomfortable, a show about life and how money messes with it.
Youve probably heard stories before of people using crowdfunding for their healthcare when insurance wont cover it. Its hard to know how to feel about these stories. Like, on the one hand, its nice to think about people supporting the ones they love; and on the other hand, it paints a bleak picture of our healthcare system. Many Americans cant afford basic medical care.
Doris and her family didnt just have to go outside the traditional insurance system, but the traditional healthcare system too. Stem cells were this new, cutting edge technology. Like, what if they could help Doris drive again or play the piano without squinting?
When Doriss family set up a GoFundMe for her, she didnt expect much to come of it. She didnt realize how beloved she was in the community, how many people, how many former students would be eager to help her restore her vision. But that was just the beginning of the surprises.
Soon after Doriss family set up the GoFundMe, money started pouring in.
Doris: I think within a week maybe two weeks wasnt it, Don? At least a week that we had it. And I was shocked that we had that much.
Reema: Doris sent Don out to buy thank you cards for everyone who donated. They had enough money for the procedure. Doris was relieved.
At that point, they were confident that stem cell treatments were the way to go. Don had been doing a lot of research online about them. Trained doctors were responsible for developing and administering the procedure. Don and Doris had spoken to the doctors on the phone. They said, this is really safe because the injections are coming from your own body.
Don: We put it in your eye, and so, you know, nothing bads gonna happen. I mean, its just part of you going back into you.
Reema: There was a chance it wouldnt work, but that risk seemed more than worth it to Doris. She and Don had selected the stem cell business that was in the pamphlet they got. Their website talks about how they collect data from all over the world, how they have more than 100 clinics in the US alone, and how theyd carefully designed sterile surgical procedures.
Doris: It would either improve my sight or it would stay the same. Uh, which, when you think youre going blind, that sounds pretty good, you know?
Reema: Doris and Don lived in Florida at the time. The closest affiliated clinic was in another state. So they packed up the car and drove.
Doris: Is it 10 hours?
Reema: Thats a long drive.
Don: Uh, no, more like 6 or 7.
Doris: Its between 8 and 10.
View original post here:
The risks of unproven stem cell treatments - Marketplace
Rothhammer, V. & Quintana, F. J. The aryl hydrocarbon receptor: an environmental sensor integrating immune responses in health and disease. Nat. Rev. Immunol. 19, 184197 (2019).
Article CAS PubMed Google Scholar
Esser, C. & Rannug, A. The aryl hydrocarbon receptor in barrier organ physiology, immunology, and toxicology. Pharmacol. Rev. 67, 259279 (2015).
Article CAS PubMed Google Scholar
Burbach, K. M., Poland, A. & Bradfield, C. A. Cloning of the Ah-receptor cDNA reveals a distinctive ligand-activated transcription factor. Proc Natl Acad Sci USA 89, 81858189 (1992).
Article CAS PubMed PubMed Central Google Scholar
Ema, M. et al. cDNA cloning and structure of mouse putative Ah receptor. Biochem. Biophys. Res. Commun. 184, 246253 (1992).
Article CAS PubMed Google Scholar
Nebert, D. W. Aryl hydrocarbon receptor (AHR): pioneer member of the basic-helix/loop/helix per-Arnt-sim (bHLH/PAS) family of sensors of foreign and endogenous signals. Prog. Lipid Res. 67, 3857 (2017).
Article CAS PubMed PubMed Central Google Scholar
Bersten, D. C., Sullivan, A. E., Peet, D. J. & Whitelaw, M. L. bHLH-PAS proteins in cancer. Nat. Rev. Cancer 13, 827841 (2013).
Article CAS PubMed Google Scholar
Gutierrez-Vazquez, C. & Quintana, F. J. Regulation of the immune response by the aryl hydrocarbon receptor. Immunity 48, 1933 (2018).
Article CAS PubMed PubMed Central Google Scholar
Shinde, R. & McGaha, T. L. The aryl hydrocarbon receptor: connecting immunity to the microenvironment. Trends Immunol. 39, 10051020 (2018).
Article CAS PubMed PubMed Central Google Scholar
Murray, I. A. & Perdew, G. H. How Ah receptor ligand specificity became important in understanding its physiological function. Int. J. Mol. Sci. 21, 9614 (2020).
Article CAS PubMed PubMed Central Google Scholar
Agus, A., Planchais, J. & Sokol, H. Gut microbiota regulation of tryptophan metabolism in health and disease. Cell Host Microbe 23, 716724 (2018).
Article CAS PubMed Google Scholar
Chiaro, C. R., Patel, R. D., Marcus, C. B. & Perdew, G. H. Evidence for an aryl hydrocarbon receptor-mediated cytochrome p450 autoregulatory pathway. Mol. Pharmacol. 72, 13691379 (2007).
Article CAS PubMed Google Scholar
Rifkind, A. B. CYP1A in TCDD toxicity and in physiology-with particular reference to CYP dependent arachidonic acid metabolism and other endogenous substrates. Drug Metab. Rev. 38, 291335 (2006).
Article CAS PubMed Google Scholar
Wei, Y. D., Bergander, L., Rannug, U. & Rannug, A. Regulation of CYP1A1 transcription via the metabolism of the tryptophan-derived 6-formylindolo[3,2-b]carbazole. Arch Biochem. Biophys. 383, 99107 (2000).
Article CAS PubMed Google Scholar
Wei, Y. D., Helleberg, H., Rannug, U. & Rannug, A. Rapid and transient induction of CYP1A1 gene expression in human cells by the tryptophan photoproduct 6-formylindolo[3,2-b]carbazole. Chem. Biol. Interact 110, 3955 (1998).
Article CAS PubMed Google Scholar
Heath-Pagliuso, S. et al. Activation of the Ah receptor by tryptophan and tryptophan metabolites. Biochemistry 37, 1150811515 (1998).
Article CAS PubMed Google Scholar
Mescher, M. & Haarmann-Stemmann, T. Modulation of CYP1A1 metabolism: from adverse health effects to chemoprevention and therapeutic options. Pharmacol. Ther. 187, 7187 (2018).
Article CAS PubMed Google Scholar
Mimura, J., Ema, M., Sogawa, K. & Fujii-Kuriyama, Y. Identification of a novel mechanism of regulation of Ah (dioxin) receptor function. Genes Dev. 13, 2025 (1999).
Article CAS PubMed PubMed Central Google Scholar
MacPherson, L. et al. Aryl hydrocarbon receptor repressor and TiPARP (ARTD14) use similar, but also distinct mechanisms to repress aryl hydrocarbon receptor signaling. Int. J. Mol. Sci. 15, 79397957 (2014).
Article PubMed PubMed Central Google Scholar
Stockinger, B., Shah, K. & Wincent, E. AHR in the intestinal microenvironment: safeguarding barrier function. Nat. Rev. Gastroenterol. Hepatol. 18, 559570 (2021).
Article CAS PubMed PubMed Central Google Scholar
Ma, W. et al. Kynurenine produced by tryptophan 2,3-dioxygenase metabolism promotes glioma progression through an aryl hydrocarbon receptor-dependent signaling pathway. Cell Biol. Int. 46, 15771587 (2022).
Article CAS PubMed Google Scholar
Xiong, J. et al. Aryl hydrocarbon receptor mediates Jak2/STAT3 signaling for non-small cell lung cancer stem cell maintenance. Exp. Cell Res. 396, 112288 (2020).
Article CAS PubMed Google Scholar
Pan, Z. Y. et al. Activation and overexpression of the aryl hydrocarbon receptor contribute to cutaneous squamous cell carcinomas: an immunohistochemical study. Diagn Pathol. 13, 59 (2018).
Article PubMed PubMed Central Google Scholar
Mohamed, H. T. et al. Inflammatory breast cancer: activation of the aryl hydrocarbon receptor and its target CYP1B1 correlates closely with Wnt5a/b-beta-catenin signalling, the stem cell phenotype and disease progression. J. Adv. Res. 16, 7586 (2019).
Article CAS PubMed Google Scholar
Mian, C. et al. AHR over-expression in papillary thyroid carcinoma: clinical and molecular assessments in a series of Italian acromegalic patients with a long-term follow-up. PLoS One 9, e101560 (2014).
Article PubMed PubMed Central Google Scholar
To, K. K., Yu, L., Liu, S., Fu, J. & Cho, C. H. Constitutive AhR activation leads to concomitant ABCG2-mediated multidrug resistance in cisplatin-resistant esophageal carcinoma cells. Mol. Carcinog. 51, 449464 (2012).
Article CAS PubMed Google Scholar
Su, J. M., Lin, P., Wang, C. K. & Chang, H. Overexpression of cytochrome P450 1B1 in advanced non-small cell lung cancer: a potential therapeutic target. Anticancer Res. 29, 509515 (2009).
PubMed Google Scholar
Schiering, C. et al. Feedback control of AHR signalling regulates intestinal immunity. Nature 542, 242245 (2017).
Article CAS PubMed PubMed Central Google Scholar
Metidji, A. et al. The environmental sensor AHR protects from inflammatory damage by maintaining intestinal stem cell homeostasis and barrier integrity. Immunity 49, 353362 e355 (2018).
Article CAS PubMed PubMed Central Google Scholar
Murray, I. A., Patterson, A. D. & Perdew, G. H. Aryl hydrocarbon receptor ligands in cancer: friend and foe. Nat. Rev. Cancer 14, 801814 (2014).
Article CAS PubMed PubMed Central Google Scholar
Panda, S. K. et al. Repression of the aryl-hydrocarbon receptor prevents oxidative stress and ferroptosis of intestinal intraepithelial lymphocytes. Immunity 56, 797812 e794 (2023).
Article CAS PubMed Google Scholar
Ly, M. et al. Diminished AHR signaling drives human acute myeloid leukemia stem cell maintenance. Cancer Res. 79, 57995811 (2019).
Article CAS PubMed Google Scholar
Singh, K. P. et al. Loss of aryl hydrocarbon receptor promotes gene changes associated with premature hematopoietic stem cell exhaustion and development of a myeloproliferative disorder in aging mice. Stem Cells Dev. 23, 95106 (2014).
Article CAS PubMed Google Scholar
Singh, K. P., Wyman, A., Casado, F. L., Garrett, R. W. & Gasiewicz, T. A. Treatment of mice with the Ah receptor agonist and human carcinogen dioxin results in altered numbers and function of hematopoietic stem cells. Carcinogenesis 30, 1119 (2009).
Article CAS PubMed Google Scholar
Opitz, C. A. et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478, 197203 (2011).
Article CAS PubMed Google Scholar
Rothhammer, V. et al. Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nat. Med. 22, 586597 (2016).
Article CAS PubMed PubMed Central Google Scholar
Shinde, R. et al. Apoptotic cell-induced AhR activity is required for immunological tolerance and suppression of systemic lupus erythematosus in mice and humans. Nat. Immunol. 19, 571582 (2018).
Article CAS PubMed PubMed Central Google Scholar
Rosser, E. C. et al. Microbiota-derived metabolites suppress arthritis by amplifying Aryl-hydrocarbon receptor activation in regulatory B cells. Cell Metab. 31, 837851 e810 (2020).
Article CAS PubMed PubMed Central Google Scholar
Granados, J. C. et al. AHR is a master regulator of diverse pathways in endogenous metabolism. Sci. Rep. 12, 16625 (2022).
Article PubMed PubMed Central Google Scholar
Cannon, A. S. et al. AhR activation leads to attenuation of murine autoimmune hepatitis: single-cell RNA-Seq analysis reveals unique immune cell phenotypes and gene expression changes in the liver. Front. Immunol. 13, 899609 (2022).
Article CAS PubMed PubMed Central Google Scholar
Dean, J. W. et al. The aryl hydrocarbon receptor cell intrinsically promotes resident memory CD8(+) T cell differentiation and function. Cell Rep. 42, 111963 (2023).
Article CAS PubMed PubMed Central Google Scholar
Stinn, A., Furkert, J., Kaufmann, S. H. E., Moura-Alves, P. & Kolbe, M. Novel method for quantifying AhR-ligand binding affinities using microscale thermophoresis. Biosensors (Basel) 11, 60 (2021).
Article CAS PubMed Google Scholar
Finn, R. N. The physiology and toxicology of salmonid eggs and larvae in relation to water quality criteria. Aquat Toxicol. 81, 337354 (2007).
Article CAS PubMed Google Scholar
Noda, S. et al. Gene expression of detoxifying enzymes in AhR and Nrf2 compound null mutant mouse. Biochem. Biophys. Res. Commun. 303, 105111 (2003).
Article CAS PubMed Google Scholar
Hannon, S. L. & Ding, X. Assessing cytochrome P450 function using genetically engineered mouse models. Adv. Pharmacol 95, 253284 (2022).
Article CAS PubMed PubMed Central Google Scholar
Degrelle, S. A., Ferecatu, I. & Fournier, T. Novel fluorescent and secreted transcriptional reporters for quantifying activity of the xenobiotic sensor aryl hydrocarbon receptor (AHR). Environ. Int. 169, 107545 (2022).
Article CAS PubMed Google Scholar
Jones, S. N., Jones, P. G., Ibarguen, H., Caskey, C. T. & Craigen, W. J. Induction of the Cyp1a-1 dioxin-responsive enhancer in transgenic mice. Nucleic Acids Res. 19, 65476551 (1991).
Article CAS PubMed PubMed Central Google Scholar
Campbell, S. J., Carlotti, F., Hall, P. A., Clark, A. J. & Wolf, C. R. Regulation of the CYP1A1 promoter in transgenic mice: an exquisitely sensitive on-off system for cell specific gene regulation. J. Cell Sci. 109, 26192625 (1996).
Article CAS PubMed Google Scholar
Galijatovic, A. et al. The human CYP1A1 gene is regulated in a developmental and tissue-specific fashion in transgenic mice. J. Biol. Chem. 279, 2396923976 (2004).
Article CAS PubMed Google Scholar
Operana, T. N., Nguyen, N., Chen, S., Beaton, D. & Tukey, R. H. Human CYP1A1GFP expression in transgenic mice serves as a biomarker for environmental toxicant exposure. Toxicol Sci. 95, 98107 (2007).
Article CAS PubMed Google Scholar
Van de Pette, M. et al. Visualizing changes in Cdkn1c expression links early-life adversity to imprint Mis-regulation in adults. Cell Rep. 18, 10901099 (2017).
Article PubMed PubMed Central Google Scholar